phentermine has been researched along with Diabetes Mellitus in 9 studies
Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and obese subjects with ≥2 weight-related comorbidities." | 9.16 | Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. ( Allison, DB; Bowden, CH; Day, WW; Gadde, KM; Garvey, WT; Look, M; Peterson, CA; Ryan, DH; Schwiers, M, 2012) |
| " Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and obese subjects with ≥2 weight-related comorbidities." | 5.16 | Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. ( Allison, DB; Bowden, CH; Day, WW; Gadde, KM; Garvey, WT; Look, M; Peterson, CA; Ryan, DH; Schwiers, M, 2012) |
| " Food and Drug Administration has approved three weight loss agents: sibutramine, orlistat, and phentermine." | 4.83 | Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. ( Pi-Sunyer, FX, 2006) |
| "To evaluate, in compliant patients, the pharmaceutical costs of treating obesity with fenfluramine/mazindol, fenfluramine/phentermine, caffeine/ephedrine, or mazindol relative to the pharmaceutical costs of treating obesity-related comorbid conditions and reducing cardiovascular risk." | 3.70 | Pharmaceutical cost savings of treating obesity with weight loss medications. ( Bray, GA; Greenway, FL; Rood, JC; Ryan, DH; Smith, SR; Tucker, EW, 1999) |
| "Most individuals with type 2 diabetes are overweight, and weight loss for them is an important therapeutic objective." | 2.69 | Pharmacologic induction of weight loss to treat type 2 diabetes. ( Bantle, JP; Kwong, CA; Raatz, SK; Redmon, JB; Swanson, JE; Thomas, W, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garvey, WT | 1 |
| Ryan, DH | 2 |
| Look, M | 1 |
| Gadde, KM | 1 |
| Allison, DB | 1 |
| Peterson, CA | 1 |
| Schwiers, M | 1 |
| Day, WW | 1 |
| Bowden, CH | 1 |
| Pi-Sunyer, FX | 1 |
| Khan, M | 1 |
| Lum, CT | 1 |
| Rao, V | 1 |
| Nightingale, SL | 1 |
| Redmon, JB | 1 |
| Raatz, SK | 1 |
| Kwong, CA | 1 |
| Swanson, JE | 1 |
| Thomas, W | 1 |
| Bantle, JP | 1 |
| Greenway, FL | 1 |
| Bray, GA | 1 |
| Rood, JC | 1 |
| Tucker, EW | 1 |
| Smith, SR | 1 |
| Campbell, CJ | 1 |
| Bhalla, IP | 1 |
| Steel, JM | 1 |
| Duncan, LJ | 1 |
| Jackson, WP | 1 |
| Vinik, AI | 1 |
| Gershberg, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Extension Study (From Study OB-303 [NCT00553787]) to Determine the Safety and Efficacy Of VI-0521 for the Long-Term Treatment Of Obesity in Adults With Obesity-Related Co-Morbid Conditions.[NCT00796367] | Phase 3 | 676 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00796367)
Timeframe: From baseline to end of treatment
| Intervention | percent weight loss (Least Squares Mean) |
|---|---|
| Placebo | -1.8 |
| VI-0521 Mid | -9.32 |
| VI-0521 Top | -10.5 |
(NCT00796367)
Timeframe: Baseline to End of Treatment
| Intervention | percent participants (Number) |
|---|---|
| Placebo | 30 |
| VI-0521 Mid | 75.2 |
| VI-0521 Top | 79.3 |
1 review available for phentermine and Diabetes Mellitus
| Article | Year |
|---|---|
Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors.
Topics: Caloric Restriction; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus; Diet; Diet, Fat-Restr | 2006 |
3 trials available for phentermine and Diabetes Mellitus
| Article | Year |
|---|---|
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
Topics: Adult; Anti-Obesity Agents; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus; | 2012 |
Pharmacologic induction of weight loss to treat type 2 diabetes.
Topics: Appetite Depressants; Behavior Therapy; Blood Glucose; Blood Pressure; Diabetes Mellitus; Diabetes M | 1999 |
A controlled trial of phentermine in obese diabetic patients.
Topics: Clinical Trials as Topic; Diabetes Mellitus; Drug Evaluation; Humans; Obesity; Phentermine | 1977 |
5 other studies available for phentermine and Diabetes Mellitus
| Article | Year |
|---|---|
Successful appetite suppression therapy with fenfluramine and phentermine in the obese diabetic transplant patient.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diabetic Nephropathies; Diet, Reducing; Drug Therapy, | 1995 |
From the Food and Drug Administration.
Topics: Appetite Depressants; Diabetes Mellitus; Emergency Medical Services; Fenfluramine; Heart Valve Disea | 1997 |
Pharmaceutical cost savings of treating obesity with weight loss medications.
Topics: Adolescent; Adult; Appetite Depressants; Caffeine; Cardiovascular Diseases; Diabetes Mellitus; Drug | 1999 |
Phentermine (Duromine) for obese diabetics.
Topics: Diabetes Mellitus; Humans; Obesity; Phentermine; Placebos | 1976 |
Use of drugs in the treatment of obesity.
Topics: Amphetamine; Cholesterol; Diabetes Mellitus; Diet, Reducing; Feeding Behavior; Female; Humans; Insul | 1972 |